Off-Label Uses of Actigall (Ursodiol)

What Ursodiol Is Approved to Treat

Ursodiol, commonly recognized by the brand name Actigall, is a naturally occurring bile acid called ursodeoxycholic acid (UDCA). The FDA has approved it for two primary purposes: dissolving small, radiolucent gallstones in patients who are not surgical candidates, and treating primary biliary cholangitis (PBC), typically under the Urso 250 or Urso Forte formulations.

The mechanism behind both uses is the same. Ursodiol replaces the more toxic, hydrophobic bile acids that accumulate in liver disease with a hydrophilic, cytoprotective version. This shift reduces bile acid-related cellular damage, lowers inflammation, and supports healthier bile flow throughout the digestive system. That same mechanism is precisely why physicians have explored ursodiol so extensively across conditions that were never part of its original approval.

Why Doctors Prescribe It Beyond the Label

Off-label prescribing is legal, common, and often clinically well-supported. Physicians can legally prescribe any approved medication for a condition outside its labeled indication when evidence suggests a benefit that outweighs the risks. For ursodiol, several factors make it an attractive off-label option.

Its safety profile is well established over decades of use. Serious adverse effects are uncommon, and the medication is generally well tolerated even with long-term administration. Its cost is relatively low compared to newer hepatic therapies. And its hepatoprotective, anti-inflammatory bile acid properties translate logically to a broad range of liver and gastrointestinal conditions. These factors together lower the threshold for physician consideration when a patient has a condition with limited approved treatment options.

Intrahepatic Cholestasis of Pregnancy

Among all off-label uses of ursodiol, intrahepatic cholestasis of pregnancy (ICP) has the most substantial evidence base and the widest clinical acceptance. ICP is a liver condition that typically develops in the third trimester, causing a buildup of bile acids in the mother's bloodstream. Symptoms include intense itching, and the condition may increase the risk of fetal complications including preterm birth and, in severe cases, stillbirth.

Ursodiol reduces circulating maternal bile acid levels and may improve fetal outcomes by limiting the transfer of bile acids across the placenta. Many obstetric guidelines outside the United States already treat ursodiol as standard of care for ICP. In the U.S., its use is widespread and clinically accepted, though it technically remains off-label. Pregnant patients experiencing symptoms of cholestasis should seek prompt evaluation rather than self-treating.

Use in Fatty Liver Disease and NASH

Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), are among the most common liver conditions globally. Ursodiol has been studied in this space because of its ability to reduce liver enzyme elevations and hepatic inflammation. Early trials using standard doses showed inconsistent results, while some research using higher-dose formulations suggested possible histological benefit.

Despite this interest, major hepatology societies do not currently recommend ursodiol as a primary therapy for NAFLD or NASH. Some clinicians prescribe it adjunctively alongside lifestyle changes or other medications. Given the mixed evidence, patients exploring this option should have a direct conversation with a hepatologist or gastroenterologist rather than pursuing self-treatment.

Other Liver and GI Conditions Where It May Be Prescribed

Beyond pregnancy cholestasis and fatty liver, ursodiol appears in clinical practice across several other conditions. The table below summarizes key uses, evidence levels, and typical dose ranges.

For primary sclerosing cholangitis (PSC), a 2010 high-dose trial raised safety concerns, and current guidelines do not recommend high-dose ursodiol for this condition. However, some hepatologists continue to use lower doses for selected patients after careful risk-benefit discussions. In cystic fibrosis-related liver disease, pediatric evidence suggests ursodiol may reduce progression of hepatic involvement, making it a more consistently supported option in that population. Post-transplant cholestatic complications represent another area where ursodiol may support bile flow and reduce hepatocellular damage.

Emerging and Investigational Applications

Research continues to expand the potential applications of ursodiol in surprising directions. Three areas have attracted notable attention in recent years.

Colorectal cancer chemoprevention is perhaps the most studied emerging use. Epidemiological data suggest that bile acid modification may reduce the recurrence of colorectal adenomas, the precursor lesions to colon cancer. Several clinical trials are ongoing to evaluate whether ursodiol can meaningfully lower this risk in high-risk populations.

Metabolic health is another frontier. Early research links UDCA to improved insulin sensitivity through modulation of the farnesoid X receptor (FXR), a bile acid-sensing nuclear receptor involved in glucose and lipid metabolism. This has prompted interest in ursodiol as a possible adjunct therapy for type 2 diabetes and metabolic syndrome, though this work remains in early stages.

Finally, a 2023 study generated interest in a possible role for ursodiol in COVID-19 protection. Researchers found that UDCA may downregulate ACE2 receptor expression in lung tissue, the entry point for the SARS-CoV-2 virus. This finding prompted investigational interest, though it has not yet translated into a clinical recommendation.

These emerging areas highlight ursodiol's broad pharmacological reach, but they also underscore the importance of waiting for rigorous clinical trial data before drawing conclusions about benefit in everyday practice.

Frequently Asked Questions

Is ursodiol safe to take off-label during pregnancy?

Ursodiol is widely used during pregnancy for intrahepatic cholestasis and has a reassuring safety record in this setting. Many international obstetric guidelines consider it standard care. That said, all medication decisions during pregnancy require close guidance from a licensed clinician who can weigh individual risks and benefits for both mother and baby.

Does ursodiol work for fatty liver disease?

Results from clinical trials for NAFLD and NASH have been mixed. Some studies showed improvements in liver enzyme levels and inflammation, but major liver society guidelines do not currently recommend ursodiol as a primary therapy for fatty liver. Some clinicians may prescribe it alongside other interventions, so discussing your specific case with a provider is important.

What is the difference between Actigall and Urso Forte?

Both contain ursodiol, the same active compound. Actigall is an older brand typically used for gallstone dissolution. Urso 250 and Urso Forte are formulations FDA-approved specifically for primary biliary cholangitis and come in higher-dose tablets. The brand name a doctor selects often reflects the intended condition, dose needed, and insurance coverage.

Can ursodiol be used long-term for liver conditions?

Yes, ursodiol is often prescribed long-term for chronic liver conditions such as primary biliary cholangitis and, off-label, primary sclerosing cholangitis. Its tolerability profile supports extended use for many patients. Periodic monitoring of liver enzymes and overall liver function is typically recommended to confirm ongoing benefit and safety.

Why would a doctor prescribe ursodiol for a condition not on the label?

Off-label prescribing is legal and common when clinical evidence supports a likely benefit. Ursodiol's hepatoprotective, anti-inflammatory properties make it a logical candidate across liver and GI conditions. Its low cost and established safety profile lower the barrier for physician consideration, particularly when approved alternatives are limited or unavailable.

The Bottom Line

Ursodiol, sold as Actigall and Urso Forte, has a range of off-label applications that extend well beyond its FDA-approved indications for gallstones and primary biliary cholangitis. From intrahepatic cholestasis of pregnancy to adjunctive use in fatty liver disease, and even investigational roles in cancer prevention and metabolic health, the evidence base varies considerably by condition. Some uses are widely accepted in clinical practice, while others remain experimental. Doctronic has conducted over 22 million AI consultations and offers 24/7 free AI consultations to help patients understand whether a medication like ursodiol may be appropriate for their situation before or between doctor visits. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.